Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age3-18
SponsorFirst Affiliated Hospital of Guangxi Medical University
About this trial
A study to evaluate the safety and preliminary efficacy of CLL-1-targeted CAR-T cell therapy in children aged 3 to 18 years with relapsed or refractory acute myeloid leukemia (r/r AML).
Eligibility criteria
Qualifiers
Voluntarily sign the ICF and are expected to complete the study's follow-up examinations and procedures.
Aged 3 to 18 years (inclusive), and body weight ≥10 kg.
Diagnosis of AML according to the 2016 WHO classification, meeting the diagnostic criteria for relapse and refractoriness as per the "Chinese Guidelines for Diagnosis and Treatment of Relapsed/Refractory Acute Myeloid Leukemia (2017 Edition)", and currently having no clinically relevant treatment options or suitable registered clinical trials available.
Confirmation of CLL-1 expression ≥50% on AML blasts by flow cytometry.
Disqualifiers
Diagnosis of APL.
History of other malignancies within 3 years prior to screening, except for adequately treated carcinoma in situ of the cervix, papillary thyroid carcinoma, basal cell or squamous cell skin cancer, localized prostate cancer treated with radical surgery, and ductal carcinoma in situ treated with radical surgery.
Evidence of CNS involvement or cranial nerve pathology.
Subjects with active infections such as hepatitis B, hepatitis C, etc., are to be excluded.
Trial design
Treatments tested in this trial
- CAR-T
Treatment groups
10 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
First Affiliated Hospital of Guangxi Medical University
Lead sponsor
Guangzhou Bio-gene Technology Co., Ltd
Collaborator
Source ClinicalTrials.gov